Please assess the completion status of the following clinical trial:

Trial Title: BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~  * Stage D1 or D2 disease (T4, N0, M0; any T, N1-3, M0; or any T, any N, M1)~* Unresponsive or refractory to prior hormonal therapy by at least 1 of the following:~  * Progression of unidimensionally measurable lesion outside of a prior radiation port~ * Progression of non-measurable disease (e.g., bone scan)~* Rising prostate-specific antigen (PSA) on at least 2 consecutive measurements taken at least 7 days apart~* PSA at least 5 ng/mL~* No brain metastases~PATIENT CHARACTERISTICS:~Age:~* Not specified~Performance status:~* Zubrod 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Absolute granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than upper limit of normal (ULN)~* SGOT or SGPT no greater than 2.5 times ULN~Renal:~* Creatinine no greater than 2.0 mg/dL OR~* Creatinine clearance at least 40 mL/min~Other:~* No other malignancy within the past 5 years except adequately treated squamous cell or basal cell skin cancer, any carcinoma in situ, or stage I or II cancer in complete remission~* No other concurrent significant active illness that would preclude study participation~* Recovered from major infections~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 28 days since prior biologic therapy and recovered~* No more than 1 prior biologic (non-cytotoxic) therapy~* No concurrent biological response modifiers~Chemotherapy:~* No prior chemotherapy for this disease~* No other concurrent chemotherapy~Endocrine therapy:~* See Disease Characteristics~* At least 28 days since prior flutamide or ketoconazole~* At least 42 days since prior bicalutamide or nilutamide~* No concurrent hormonal therapy, except luteinizing hormone-releasing hormone therapy~* No concurrent corticosteroids~Radiotherapy:~* See Disease Characteristics~* Prior radiotherapy to less than 30% of bone marrow allowed~* No prior strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium~* At least 28 days since prior radiotherapy and recovered~* No concurrent radiotherapy~Surgery:~* Recovered from prior surgery~* Prior orchiectomy allowed~Other:~* No concurrent unconventional therapy (e.g., St. John's Wort, PC-SPES, or other herbal remedy for prostate cancer)~* Not planning to begin bisphosphonate therapy (patients already receiving bisphosphonates are eligible provided they have progressive disease)

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).